Response to SARS-CoV-2 Initial Series and Additional Dose Vaccine in Pediatric Patients with Predominantly Antibody Deficiency

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Aug 14

PMID 37575247

Authors

Megha Tandon

Daniel V DiGiacomo

Baijun Zhou

Paul Hesterberg

Chen E Rosenberg

Sara Barmettler

Jocelyn R Farmer

Affiliations

Soon will be listed here.

Abstract

Data regarding response to SARS-CoV-2 immunization in pediatric patients with predominantly antibody deficiency (PAD) is limited. We evaluated SARS-CoV-2 immunization response by anti-SARS-CoV-2-spike antibody level in 15 pediatric PAD patients. These data were compared to a published cohort of adult PAD patients (n=62) previously analyzed following SARS-CoV-2 immunization at our single center institution. We evaluated demographics, clinical characteristics, immunophenotype, infection history, and past medication use by chart review. Following a two-dose monovalent initial series SARS-CoV-2 immunization, mean anti-SARS-CoV-2-spike antibody levels were significantly higher in pediatric PAD patients compared to adult PAD patients (2,890.7 vs. 140.1 U/mL; p<0.0001). Pediatric PAD patients with low class-switched memory B-cells, defined as <2% of total CD19+ B-cells, had significantly lower mean anti-SARS-CoV-2-spike antibody levels than those without (p=0.02). Following a third-dose monovalent SARS-CoV-2 immunization, the mean anti-SARS-CoV-2-spike antibody levels in pediatric PAD patients significantly increased (2,890.7 to 18,267.2 U/mL; p<0.0001). These data support Centers for Disease Control guidelines regarding three-part SARS-CoV-2 vaccine series, including in the pediatric PAD patient demographic.

Citing Articles

A Cross-Sectional Study of Health-Related Quality of Life in Patients with Predominantly Antibody Deficiency.

Elmoursi A, Zhou B, Ong M, Hong J, Pak A, Tandon M J Clin Immunol. 2024; 44(8):173.

PMID: 39110257 PMC: 11658799. DOI: 10.1007/s10875-024-01781-y.

A Cross-Sectional Study of Health-Related Quality of Life in Patients with Predominantly Antibody Deficiency.

Elmoursi A, Zhou B, Ong M, Hong J, Pak A, Tandon M Res Sq. 2024; .

PMID: 39070620 PMC: 11276022. DOI: 10.21203/rs.3.rs-4612913/v1.

An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.

Chang-Rabley E, van Zelm M, Ricotta E, Edwards E Vaccines (Basel). 2024; 12(6).

PMID: 38932404 PMC: 11209597. DOI: 10.3390/vaccines12060675.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency.

Zhang A, Elmoursi A, DiGiacomo D, Zhou B, Tandon M, Hong J J Allergy Clin Immunol Glob. 2024; 3(2):100234.

PMID: 38544577 PMC: 10965812. DOI: 10.1016/j.jacig.2024.100234.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Durandy A, Kracker S, Fischer A . Primary antibody deficiencies. Nat Rev Immunol. 2013; 13(7):519-33. DOI: 10.1038/nri3466. View

Bitzenhofer M, Suter-Riniker F, Moor M, Sidler D, Horn M, Gschwend A . Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. PLoS One. 2022; 17(6):e0268780. PMC: 9182562. DOI: 10.1371/journal.pone.0268780. View

Pawelec G . Immunity and ageing in man. Exp Gerontol. 2006; 41(12):1239-42. DOI: 10.1016/j.exger.2006.09.005. View

Suhandynata R, Bevins N, Tran J, Huang D, Hoffman M, Lund K . SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. J Appl Lab Med. 2021; 6(5):1109-1122. PMC: 8409063. DOI: 10.1093/jalm/jfab080. View

Durkee-Shock J, Keller M . Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022; 129(5):562-571.e1. PMC: 9212748. DOI: 10.1016/j.anai.2022.06.009. View

Bonilla F, Khan D, Ballas Z, Chinen J, Frank M, Hsu J . Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015; 136(5):1186-205.e1-78. DOI: 10.1016/j.jaci.2015.04.049. View

Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M . Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. J Allergy Clin Immunol Pract. 2021; 9(7):2904-2906.e2. PMC: 8059325. DOI: 10.1016/j.jaip.2021.04.017. View

Erra L, Uriarte I, Colado A, Paolini M, Seminario G, Fernandez J . COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity. J Clin Immunol. 2022; 43(2):271-285. PMC: 9574808. DOI: 10.1007/s10875-022-01382-7. View

10.

Frasca D, Riley R, Blomberg B . Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol. 2005; 17(5):378-84. DOI: 10.1016/j.smim.2005.05.005. View

11.

Bousfiha A, Moundir A, Tangye S, Picard C, Jeddane L, Al-Herz W . The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol. 2022; 42(7):1508-1520. DOI: 10.1007/s10875-022-01352-z. View

12.

Ma A, Leung D, Chan E, Chim S, Cheng S, Ho F . Antibody responses to 2 doses of mRNA COVID-19 vaccine in pediatric patients with kidney diseases. Kidney Int. 2022; 101(5):1069-1072. PMC: 8881810. DOI: 10.1016/j.kint.2022.01.035. View

13.

Rubio-Acero R, Castelletti N, Fingerle V, Olbrich L, Bakuli A, Wolfel R . In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients. Infect Dis Ther. 2021; :1-14. DOI: 10.1007/s40121-021-00475-x. View

14.

Bonilla F, Barlan I, Chapel H, Costa-Carvalho B, Cunningham-Rundles C, de la Morena M . International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2015; 4(1):38-59. PMC: 4869529. DOI: 10.1016/j.jaip.2015.07.025. View

15.

Frenck Jr R, Klein N, Kitchin N, Gurtman A, Absalon J, Lockhart S . Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3):239-250. PMC: 8174030. DOI: 10.1056/NEJMoa2107456. View

16.

Weiskopf D, Weinberger B, Grubeck-Loebenstein B . The aging of the immune system. Transpl Int. 2009; 22(11):1041-50. DOI: 10.1111/j.1432-2277.2009.00927.x. View

17.

Abolhassani H, Delavari S, Landegren N, Shokri S, Bastard P, Du L . Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19. J Allergy Clin Immunol. 2022; 150(5):1059-1073. PMC: 9472457. DOI: 10.1016/j.jaci.2022.09.005. View

18.

Dunay G, Barroso M, Woidy M, Danecka M, Engels G, Hermann K . Long-Term Antibody Response to SARS-CoV-2 in Children. J Clin Immunol. 2022; 43(1):46-56. PMC: 9483535. DOI: 10.1007/s10875-022-01355-w. View

19.

Patel E, Bloch E, Clarke W, Hsieh Y, Boon D, Eby Y . Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. J Clin Microbiol. 2020; 59(2). PMC: 8111143. DOI: 10.1128/JCM.02257-20. View

20.

Choi J, Choi S, Yun K . Risk Factors for Severe COVID-19 in Children: A Systematic Review and Meta-Analysis. J Korean Med Sci. 2022; 37(5):e35. PMC: 8822112. DOI: 10.3346/jkms.2022.37.e35. View